Skip to content

Ionis Pharmaceuticals

US · IONS #1749 by market cap Listed 1970
26.58 -0.64 -2.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Price chart

Pre-market 26.83 -1.43%
After-hours 26.76 +0.68%
Overnight 27.21 -0.04%
86.3326.5826.582026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IONS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -59.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 12.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 17.1% Better than 78%
Free cash flow CAGR (3Y) -72.0% Better than 1%
Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 98.3% Better than 99%
Operating margin -40.4% Better than 10%
Net margin -40.4% Better than 9%
Return on equity -70.8% Better than 7%
Return on invested capital -14.0% Better than 16%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -55.5% Better than 4%
6-month return -64.8% Better than 3%
12-month return (ex latest month) -43.6% Better than 4%
Distance below 52-week high 69.4% Better than 6%
Financial Health C-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.8x Better than 80%
Debt to assets 58.6% Better than 9%
Interest coverage -3.5x Better than 18%
Free cash flow / net income 105.2% Better than 42%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 94.7% Better than 77%
Upside to average target 172.3% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.53%
1M -41.45%
3M -54.77%
6M -64.59%
YTD -66.40%
1Y -63.65%
3Y -46.49%
5Y -16.91%

Key statistics

Price & volume

Prev close
27.22
Open
26.93
Day range
26.53 - 28.07
Avg price
27.02
Volume
3.19M
Turnover
86.09M
Amplitude
5.66%
52-week range
26.53 - 86.74

Valuation

P/E
-11.17
P/E (TTM)
-7.93
P/B
11.24
EPS
-2.38
Net profit
-396.38M
Net assets
393.71M

Share structure

Market cap
4.43B
Float cap
4.39B
Shares out
166.55M
Float shares
165.18M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 0% of range
26.53 86.74

69.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-229.40M net over the window

Short interest

Shares short
21.17M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ionis Pharmaceuticals (IONS)?

Ionis Pharmaceuticals last traded at 26.58. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ionis Pharmaceuticals's market cap?

About 4.43B.

What is the P/E ratio of Ionis Pharmaceuticals?

The trailing twelve-month P/E is -7.93. The Valuation tab shows it against the stock's own five-year range.

Does Ionis Pharmaceuticals pay a dividend?

Ionis Pharmaceuticals does not currently pay a regular dividend.

Is Ionis Pharmaceuticals a buy according to analysts?

The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 72.39, which implies 172.3% upside from the current price. This is not investment advice.

What is Ionis Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ionis Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:59:29 · For reference only, not investment advice and not tailored to your situation.

Ionis Pharmaceuticals discussion 0 comments

Add a comment